Forte Biosciences, Inc.
FBRX
$6.32
-$0.34-5.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.63% | -28.28% | 273.51% | 66.88% | 14.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.20% | -15.53% | 41.89% | 13.84% | 29.20% |
| Operating Income | -15.20% | 15.53% | -41.89% | -13.84% | -29.20% |
| Income Before Tax | -21.85% | 15.70% | -40.64% | -9.88% | -20.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.85% | 15.70% | -40.64% | -9.88% | -20.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.85% | 15.70% | -40.64% | -9.88% | -20.40% |
| EBIT | -15.20% | 15.53% | -41.89% | -13.84% | -29.20% |
| EBITDA | -15.15% | 15.62% | -- | -- | -29.31% |
| EPS Basic | 63.26% | 30.90% | 35.84% | 49.91% | 45.15% |
| Normalized Basic EPS | 63.27% | 30.90% | 35.84% | 49.91% | 45.15% |
| EPS Diluted | 63.26% | 30.90% | 35.84% | 49.91% | 45.15% |
| Normalized Diluted EPS | 63.27% | 30.90% | 35.84% | 49.91% | 45.15% |
| Average Basic Shares Outstanding | 231.69% | 21.99% | 119.17% | 119.36% | 119.50% |
| Average Diluted Shares Outstanding | 231.69% | 21.99% | 119.17% | 119.36% | 119.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |